Dihydrotanshinone I (DTSI) significantly inhibits mTOR phosphorylation via the AMPK/mTOR signaling pathway, thereby enhancing autophagy, increasing Aβ clearance, and reducing tau phosphorylation, which highlights the potential of DTSI in the treatment of AD (Bao et al., 2020). The gene discussed is MAPT; the disease is Alzheimer disease.